Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01 Clinical Trial Not Allowed)

The contract pertains to the Center for Inherited Disease Research (CIDR), which provides high-throughput genotyping and sequencing services alongside statistical genetics support to facilitate the identification of genes or genetic modifications linked to human health and disease. CIDR's role is to enhance the characterization of well-phenotyped specimens by integrating genotype or next-generation sequence data, leveraging advanced genomic platforms and expertise that exceed what individual investigator laboratories can efficiently perform. This initiative is NIH-wide and managed by the National Human Genome Research Institute (NHGRI), ensuring access to cutting-edge genomic technologies and statistical analysis essential for advancing genetic research. The contract, titled "Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01 Clinical Trial Not Allowed)," was posted on June 9, 2026. It is part of an NIH effort under the Department of Health and Human Services, designed to support research projects by providing access to CIDR's resources without involving clinical trials. Interested parties can contact the CIDR Team via the provided email and find more details on the official grants website. The contract emphasizes the provision of state-of-the-art genomic and statistical services to accelerate discovery in genetic contributions to disease within a federally supported framework.